Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases

European Journal of Surgical Oncology

Volumn 34, Issue 6, 2008, Pages 609-614

  Morris Stiff, G ^a   Tan, Y M ^b   Vauthey, J N ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Chemotherapy associated steatohepatits; Colorectal liver metastases; Irinotecan; Liver resection; Oxaliplatin; Sinusoidal obstruction syndrome

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER SURVIVAL; COLORECTAL CANCER; FATTY LIVER; HIGH RISK POPULATION; HUMAN; LIVER FAILURE; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; LIVER SINUSOID; LIVER VENOOCCLUSIVE DISEASE; MORTALITY; PATIENT MONITORING; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; SINUSOIDAL OBSTRUCTION SYNDROME;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FATTY LIVER; HEPATECTOMY; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS;

EID: 43449090668     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.07.007     Document Type: Review

References (50)

1. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235 (2002) 759-766
2. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcome following hepatic resection, radiofrequency ablation and combined resection/ablation for colorectal liver metastases. Ann Surg 239 (2004) 818-827
3. Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., and Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography. Ann Surg 240 (2004) 438-447
4. Pawlik T.M., Scoggins C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241 (2005) 715-722
5. National Institute for Health and Clinic Excellence. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. www.nice.org.uk/TA093guidance.
6. ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 18 Suppl 2 (2007) 25-26
7. Gruenberger T., Sorbye H., Dubois M., et al. Tumour response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomised phase III trial. J Clin Oncol 24 (2006) 3500
8. Nordlinger B., Sorbye H., Collette L., et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 25 (2007) [Abstract LBA5]
9. Bismuth H., Adam R., Lévi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224 (1996) 509-522
10. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict long-term survival. Ann Surg 240 (2004) 644-658
11. Leonard G.D., Brenner B., and Kemeny N.E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23 (2005) 2038-2048
12. Folprecht G.A., Grothey A., Alberts S., Raab H.R., and Köhne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005) 1311-1319
13. DeLeve L.D., Shulman H.M., and McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 (2002) 27-37
14. Willmot F.C., and Robertson G.W. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet 2 (1920) 848-849
15. DeLeve L.D., McCuskey R.S., Wang X., et al. Characterization of a reproducible model of hepatic veno-occlusive disease. Hepatology 29 (1999) 1779-1791
16. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
17. Tisman G., MacDonald D., Shindell N., et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 22 (2004) 3202-3204
18. Karoui M., Penna C., Amin-Hashem M., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006) 1-7
19. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in ninety-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
20. Julie C., Lutz M.P., Aust D., et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: Results of the EORTC Intergroup phase III study 40983. J Clin Oncol 25 (2007) [Abstract 241]
21. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24 (2006) 4983-4990
22. Washington K., Lane K.L., and Meyers W.C. Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol 17 (1993) 1151-1158
23. Cwikiel M., Zhang B., Eskilsson J., Wieslander J.B., and Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 9 (1995) 561-576
24. Mulhall B.P., Ong J.P., and Younossi Z.M. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 17 (2002) 1136-1143
25. Kooby D.A., Fong Y., Suriawinata A., et al. Impact of perioperative outcome following hepatic resection. J Gastrointest Surg 7 (2003) 1034-1044
26. Hamaguchi M., Kojima T., Takeda N., et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
27. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
28. Fong Y., and Bentrem D.J. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243 (2006) 8-9
29. Peppercorn P.D., Reznek R.H., Wilson P., Slevin M.L., and Gupta R.K. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77 (1998) 2008-2011
30. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irrinotecan or oxaliplatin on respectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
31. Kooby D.A., Stockman J., Ben-Porat L., et al. Influence of transfusions on perioperative and long-term outcome in patients following resection for colorectal metastases. Ann Surg 237 (2003) 860-870
32. Behrns K.E., Tsiotos G.G., DeSouza N.F., Krishna M.K., Ludwig J., and Nagorney D.M. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2 (1998) 292-298
33. Belghiti J., Hiramatsu K., Benosit S., Massault P.P., Sauvanet A., and Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191 (2000) 38-46
34. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., and Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
35. Selzner M., Rudiger H.A., Sindram D., Madden J., and Clavien P.A. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 32 (2000) 1280-1288
36. Koneru B., and Dikdan G. Hepatic steatosis and liver transplantation current clinical and experimental perspectives. Transplantation 73 (2002) 325-330
37. Jones O.M., Rees M., John T.G., Bygrave S., and Plant G. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 92 (2005) 1165-1168
38. Fiorini R.N., Kirtz J., Periyasamy B., et al. Development of an unbiased method for the estimation of liver steatosis. Clin Transplant 18 (2004) 700-706
39. Vauthey J.-N., Chaoui A., Do K.-A., et al. Standardized measurement of the future liver remnant prior to extended resection: methodology and clinical associations. Surgery 127 (2000) 512-519
40. Mullin E.J., Metcalfe M.S., and Maddern G.J. How much liver resection is too much?. Am J Surg 190 (2005) 87-97
41. Oliva M.R., Mortele K.J., Segatto E., et al. Computed tomography features of non-alcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 30 (2006) 37-43
42. Elias D., Youssef O., Sideris L., et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 86 (2004) 4-9
43. Benoist S., Broquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 24 (2006) 3939-3945
44. Welsh F.K.S., Tilney H.S., Tekkis P.P., John T.G., and Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96 (2007) 1037-1042
45. Abdalla E.K., Barnett C.C., Doherty D., Curley S.A., and Vauthey J.-N. Extended hepatectomy in patients with hepatobiliary malignancies with and without portal vein embolization. Arch Surg 137 (2002) 675-681
46. Vauthey J.-N., Pawlik T.M., Abdalla E.K., et al. Is extended hepatectomy for hepatobiliary malignancy justified?. Ann Surg 239 (2004) 722-732
47. Makuuchi M., Thai B.L., Takayasu K., et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107 (1990) 521-527
48. Howdieshell T.R., Callaway D., Webb W.L., et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 96 (2001) 173-182
49. Assy N., Spira G., Paizi M., et al. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol 30 (1999) 911-915
50. Ellis L.M., Curley S.A., and Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23 (2005) 4853-4855